Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C8H10N6.H2O4S |
| Molecular Weight | 288.284 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OS(O)(=O)=O.NNC1=NN=C(NN)C2=C1C=CC=C2
InChI
InChIKey=BWHAMWGGORIDBK-UHFFFAOYSA-N
InChI=1S/C8H10N6.H2O4S/c9-11-7-5-3-1-2-4-6(5)8(12-10)14-13-7;1-5(2,3)4/h1-4H,9-10H2,(H,11,13)(H,12,14);(H2,1,2,3,4)
| Molecular Formula | C8H10N6 |
| Molecular Weight | 190.2052 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
| Molecular Formula | H2O4S |
| Molecular Weight | 98.078 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans. | 2014-01 |
|
| Autoimmune hepatitis triggered by nitrofurantoin: a case series. | 2010-09-23 |
|
| Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. | 2010-05 |
|
| [Drugs during preeclampsia. Fetal risks and pharmacology]. | 2010-04 |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate in serum using luminol and diperiodatocuprate (III) system. | 2010-01 |
|
| Xenobiotic exposure and autoimmune hepatitis. | 2010 |
|
| Hemodynamic, morphometric and autonomic patterns in hypertensive rats - Renin-Angiotensin system modulation. | 2010 |
|
| Emitting species in chemiluminescence reactions with acidic potassium permanganate: a re-evaluation based on new spectroscopic evidence. | 2009-09 |
|
| Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development. | 2009 |
|
| Effects of dihydralazine on renal water and aquaporin-2 excretion in humans. | 2009 |
|
| [Eclampsia at a teaching hospital in Ivory Coast: management, outcome and prognostic factors]. | 2008-07 |
|
| Regression of glomerulosclerosis in subtotally nephrectomized rats: effects of monotherapy with losartan, spironolactone, and their combination. | 2008-07 |
|
| Chemiluminescence investigation of carbon dioxide-enhanced oxidation of dihydralazine sulfate by peroxynitrite and its application to pharmaceutical analysis. | 2008-06-02 |
|
| Nitric oxide-deficiency regulates hepatic heme oxygenase-1. | 2008-02 |
|
| Maternal and fetal hemodynamic effects induced by nitric oxide donors and plasma volume expansion in pregnancies with gestational hypertension complicated by intrauterine growth restriction with absent end-diastolic flow in the umbilical artery. | 2008-01 |
|
| Progress curve analysis of CYP1A2 inhibition: a more informative approach to the assessment of mechanism-based inactivation? | 2007-12 |
|
| Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. | 2007-06 |
|
| Method development for dihydralazine with HPLC-MS/MS--an old but tricky substance in human plasma. | 2007-01-17 |
|
| Antihypertensive therapy in patients with pre-eclampsia: A prospective randomised multicentre study comparing dihydralazine with urapidil. | 2006-08 |
|
| Positive effects of nitric oxide on left ventricular function in humans. | 2006-07 |
|
| [Hypertension in pregnancy]. | 2006-03 |
|
| Dihydralazine treatment limits liver injury after hemorrhagic shock in rats. | 2006-03 |
|
| Changes in metabolism and blood flow following catecholamine stimulation in the synovial membrane measured with microdialysis. | 2006-02 |
|
| Evaluation of a strict protocol approach in managing women with severe disease due to hypertension in pregnancy: a before and after study. | 2005-09-30 |
|
| Morbidity and development in childhood of infants born after temporising treatment of early onset pre-eclampsia. | 2005-07 |
|
| Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. | 2005-03 |
|
| Isolated sarcoid granulomatous interstitial nephritis responding to infliximab therapy. | 2005-02 |
|
| Hypertension in children with chronic renal failure. | 2005 |
|
| Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. | 2005 |
|
| Flow injection chemiluminescence determination of dihydralazine sulphate based on permanganate oxidation sensitized by rhodamine B. | 2004-10-28 |
|
| Flow-injection chemiluminescence determination of dihydralazine sulfate based on hexacyanoferrate(III) oxidation sensitized by eosin Y. | 2004-10-08 |
|
| Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. | 2004-10 |
|
| Reactivity of hydrazinophthalazine drugs with the lipid peroxidation products acrolein and crotonaldehyde. | 2004-09-21 |
|
| Site-specific 99mTc-labeling of antibody using dihydrazinophthalazine (DHZ) conjugation to Fc region of heavy chain. | 2004-09 |
|
| 3,6-Bis(2-pyridyl)di-1,2,4-triazolo[3,4-a:4',3'-c]phthalazine. | 2004-09 |
|
| [Determination of five components in compound hypotensive tablet by HPLC]. | 2004-08 |
|
| Plasma volume and blood pressure regulation in hypertensive pregnancy. | 2004-07 |
|
| The impact of maternal plasma volume expansion and antihypertensive treatment with intravenous dihydralazine on fetal and maternal hemodynamics during pre-eclampsia: a clinical, echo-Doppler and viscometric study. | 2004-04 |
|
| Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity. | 2004-03 |
|
| [Reversible loss of vision in severe preeclampsia: case report and review of the literature]. | 2003-12-23 |
|
| [When hypertension becomes an emergency case: lower the blood pressure, but slowly!]. | 2003-05-29 |
|
| Human cytochrome P450 2E1 is a major autoantigen associated with halothane hepatitis. | 1996-10-01 |
|
| Additive effects of dihydralazine during enflurane or isoflurane hypotensive anaesthesia for spinal fusion. | 1988-05 |
|
| Comparative study on the short-term effects of angiotensin converting enzyme inhibitors (Lopirin, SQUIBB and Tensiomin), and dihydralazine in chronic cardiac failure. | 1988 |
|
| [Liver lesions induced by dihydralazine and propranolol]. | 1985 |
|
| Mode of antihypertensive action of nitrendipine. | 1984 |
|
| Action of vasodilating drugs on small and large arteries of hypertensive patients. | 1983-07-01 |
|
| Side-effects with long-term labetalol: an open study of 251 patients in a single centre. | 1983 |
|
| [Rare liver damage caused by an antihypertensive and anti-arrhythmic agents]. | 1980-04-01 |
|
| Effects of acute hypotension and hypertension on serum TSH concentrations in male rats. | 1979-10 |
Patents
Sample Use Guides
The influence of a pure afterload reduction on systolic time intervals and various echocardiographic indices was assessed in six healthy volunteers, who underwent a single blind placebo controlled trial of three regimens of intravenous dihydralazine (6.25, 12.5, and 25.0 mg).
Route of Administration:
Intravenous
In Vitro Use Guide
Curator's Comment: In mice bone marrow cells, dihydralazine induced a modest but statistically significant increase over controls in the frequency of sister chromatid exchanges, the rank of potencies being in this case dihydralazine greater than endralazine greater than hydralazine. In the Ames reversion test all three drugs behaved as direct-acting mutagens of low potency, whose activity was not influenced by rat liver nor by mouse liver or lung S-9 fractions. Hydralazine and dihydralazine elicited mixed genetic mechanisms of mutations, while endralazine exclusively induced frameshift errors in Salmonella DNA.
Unknown
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:32:56 GMT 2025
by
admin
on
Mon Mar 31 17:32:56 GMT 2025
|
| Record UNII |
1C2B1W91NK
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
SUB130439
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
ALTERNATIVE | |||
|
235959
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | RxNorm | ||
|
m4457
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | Merck Index | ||
|
CHEMBL35505
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
1C2B1W91NK
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
SUB01702MIG
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
DTXSID10223501
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
100000092770
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
81764
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
DBSALT002931
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
7327-87-9
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
C81520
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY | |||
|
230-808-0
Created by
admin on Mon Mar 31 17:32:56 GMT 2025 , Edited by admin on Mon Mar 31 17:32:56 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE | |||
|
SOLVATE->ANHYDROUS |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |